Pay to Marwadi

Company Profile

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE6281.30-71.4 (-1.12 % )
PREV CLOSE (Rs.) 6352.70
OPEN PRICE (Rs.) 6352.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 419
TODAY'S LOW / HIGH (Rs.)6153.20 6479.75
52 WK LOW / HIGH (Rs.)1698.55 7450
NSE6322.15 -37.8 (-0.59 % )
PREV CLOSE(Rs.) 6359.95
OPEN PRICE (Rs.) 6400.00
BID PRICE (QTY) 6322.15 (190 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 16249
TODAY'S LOW / HIGH(Rs.) 6234.05 6450.00
52 WK LOW / HIGH (Rs.)1695 7318.3

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.16
TTM EPS (Rs.) 246.69
P/E Ratio 25.46
Book Value (Rs.) 940.81
Face Value (Rs.) 10
MCap (Rs. in Mn) 80588.38
Price/Earning (TTM) 21.59
Price/Sales (TTM) 5.10
Price/Book (MRQ) 6.68
PAT Margin (%) 13.69
ROCE (%) 20.99
Incorporation Year : 1984

Management Info :

Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director

Registered Office :

Address : 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone : 040-67611600 / 67611700

Registrar's Details : K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
04Mar03-04-2024$Neuland Laboratories informs about analyst meet Neuland Laboratories informs
Neuland Laboratories has informed that the Company’s management will be participating in the group analyst/ investor meetings as on March 7, 2024.

The above information is a part of company’s filings submitted to BSE.

Neuland Laboratories has informed that the Company’s manageme..
26Feb02-26-2024$Neuland Laboratories informs about issuance of letter of confirmation Neuland Laboratories informs

Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-RTAMB/P/CIR /2022/8 dated January 25, 2022, Neuland Laboratories has informed that the Company has approved issuance of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced by the shareholder(s), as per the details enclosed. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to the Regulation 39(3) of the SEBI (Listing Obligatio..
01Jan01-01-2024$ Intimation Of S&P Global ESG Score, 2023 Intimation Of S&P Global ES
As part of our enduring commitment to environmental, social and governance (ESG) efforts, we would like to inform that our Company was awarded a Corporate Sustainability Assessment (CSA) score of 58 out of 100 by S&P Global. The Company''s score placed it in 94th percentile among 348 companies considered as industry peers during 2023.
As part of our enduring commitment to environmental, social and..
13Nov11-13-2023$Neuland Laboratories informs about transcript of earnings call Neuland Laboratories informs
Neuland Laboratories has informed that it enclosed the transcript of the Earnings call for the quarter and half year ended September 30, 2023, conducted on November 7, 2023. Also informed that this transcript of the call has been uploaded on its website. The weblink to access it: https://www.neulandlabs.com/investors/investor-updates/announcements/

The above information is a part of company’s filings submitted to BSE.

Neuland Laboratories has informed that it enclosed the transcri..
20Oct10-20-2023$Neuland Laboratories informs about loss of share certificate(s) Neuland Laboratories informs

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Neuland Laboratories has informed that the shareholder(s) has reported to the Company about the loss of his/her share certificate(s) and has requested for issue of ‘Letter of Confirmation’ in lieu of physical share certificate(s). The particulars relating to the loss of share certificate(s) are enclosed. 

The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations &..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit807.011631.19
Gross Profit 1037.8 2152.13
Operating Profit 1226.652810.56
Net Sales 3928.2811911.98
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap ( in Cr)
57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap ( in Cr)
18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap ( in Cr)
102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap ( in Cr)
91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap ( in Cr)
32917.29
Shareholding Pattern More
NON-INSTITUTION 38.08 %
PROMOTERS 32.8 %
MUTUAL FUNDS/UTI 1.83 %
GOVERNMENT 0.4 %
FI/BANKS/INSURANCE 0 %
FII 0 %
F & O Quotes